BRAF and melanoma: Decades of clinical trials have been dedicated to studying adjuvant therapy for melanoma, encompassing interventions such as high‐dose interferon‐α, immune checkpoint inhibitors (pembrolizumab, nivolumab), targeted therapy (dabrafenib‐trametinib for BRAF mutant melanoma), and chemotherapy.